In all, 26 patients with advanced GI tract cancer (among whom 23 had liver metastases) were treated in a phase II trial with a 24-h infusion of high-dose ifosfamide and mesna (5 g/m2). Two PR, 1 CR and 4 NC were evidenced among 23 patients evaluable for response. The toxicity was significant and mainly expressed in the hair, digestive tract, granulocytes and CNS. One patient died from CNS and kidney toxicities. Only patients with good clinical indices, normal serum albumin and creatinine levels and without pelvic involvement seemed to be candidates to benefit from the treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF00267954 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase II Trial of Brain MRI Surveillance in Stage IV Breast Cancer.
Neuro Oncol
January 2025
Department of Breast Oncology, Moffitt Cancer Center.
Background: Screening of asymptomatic stage IV breast cancer with brain MRIs is currently not recommended by National Comprehensive Cancer Network (NCCN) Guidelines. The incidence of asymptomatic brain metastasis is not well documented.
Methods: The study is designed as a single arm, phase II trial, with the goal of investigating surveillance brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
Traditional herbal medicine for Guillain-Barré syndrome: A systematic review and meta-analysis.
Heliyon
January 2025
Stroke and Neurological Disorders Center, Kyung Hee University College of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
Background: Guillain-Barré syndrome (GBS) is a rapid-onset disease caused by the immune system damaging the peripheral nervous system. Since most standardized treatments for GBS focus on acute phase treatment, there are limitations to the rehabilitation and management of general conditions. In East Asian countries, herbal medicine has been used to treat GBS and aid rehabilitation.
View Article and Find Full Text PDFEffect of acupressure on childbirth outcomes in nulliparous women: A randomized clinical trial.
J Educ Health Promot
December 2024
Master in Biostatistics, Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran.
Background: Non-pharmaceutical method is one of the conventional methods of reducing labor pain. Acupressure is suggested as an effective method for reducing labor pain with favorable effects on the outcome of childbirth. Different acupressure methods are suggested for this purpose; the most effective one has to be investigated.
View Article and Find Full Text PDFNon-invasive quantification of bone (re) modeling dynamics in adults with osteogenesis imperfecta treated with Setrusumab using timelapse HR-pQCT.
J Bone Miner Res
January 2025
Research Centre, Shriners Hospital for Children-Canada, Montreal, Canada.
Timelapse imaging using high-resolution peripheral quantitative computed tomography (HR-pQCT) has emerged as a noninvasive method to quantify bone (re)modelling. However, there is no consensus on how to perform the procedure. As part of the ASTEROID phase-2b multicenter trial, we used 29 same-day repeated scans from adults with osteogenesis imperfecta (OI) to identify a method that minimized measurement error.
View Article and Find Full Text PDFVvax001, a Therapeutic Vaccine for Patients with HPV16-positive High-grade Cervical Intraepithelial Neoplasia: a Phase II Trial.
Clin Cancer Res
January 2025
University Medical Center Groningen, Groningen, Netherlands.
Purpose: Human papillomavirus (HPV) infection is the major cause of (pre)malignant cervical lesions. We previously demonstrated that Vvax001, a replication-incompetent Semliki Forest virus (SFV) vaccine encoding HPV type 16 (HPV16) E6 and E7, induced potent anti-E6 and -E7 cytotoxic T-cell responses. Here, we investigated the clinical efficacy of Vvax001 in patients with HPV16-positive cervical intraepithelial neoplasia grade 3 (CIN3).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!